In this study, we aim to investigate the therapeutic efficacy and molecular mechanism underlying RC48 alone or in combination with dabrafenib in both in vitro and in vivo models of BRAF-mutant cutaneous melanoma. This evidence concerns the gene BRAF and cutaneous melanoma.